Her2 Low News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Her2 low. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Her2 Low Today - Breaking & Trending Today

Dr Tolaney on the Real-World Efficacy of T-DXd in HER2+ or HER2-Low Breast Cancer

Sara M. Tolaney, MD, MPH, discusses the real-world efficacy of fam-trastuzumab deruxtecan in patients with HER2-positive or HER2-low metastatic breast cancer, including patients who experienced changes in HER2 status during the treatment course. ....

San Antonio , United States , Saram Tolaney , Division Of Breast Oncology , Susanf Smith Center , Harvard Medical School , Dana Farber Cancer Institute , Duke Cancer Center , Breast Oncology , Antonio Breast Cancer Symposium , Onclive Tv , Breast Cancer , T Dxd , Her2 Low ,

Antibody-Drug Conjugates in Breast Cancer

A breast medical oncologist provides insights on antibody-drug conjugates in the breast cancer space and discusses ongoing research. ....

Antibody Drug Conjugates , Breast Cancer , Breast Cancer Treatment , T Dm1 , Trastuzumab Deruxtecan , Her2 Low ,

Second-Line Therapy for Metastatic TNBC

Shay Elkins, a patient with triple negative breast cancer, shares her experience of relapse six months post-treatment, eventually leading her to seek a second opinion for her recurring symptoms. Dr. Noor Abuhadra discusses second-line treatment options for metastatic triple negative breast cancer, emphasizing newer therapies like antibody drug conjugates and PARP inhibitors, and highlights the evolving landscape that offers hope for patients. ....

Shay Elkins , Noor Abuhadra , Metastatic Triple Negative Breast Cancer , Overcoming Challenges , Diagnosis Treatment , Online Therapy , Triple Negative Breast Cancer , Second Line Therapy , Refractory Disease , Nurse Support , Treatment Plan , Antibody Drug Conjugates , Parp Inhibitors , Sacituzumab Govitecan , Her2 Low , Fam Trastuzumab Deruxtecan , Her2 Expression , Chemotherapy Classes , Recurrence Risk , Treatment Landscape ,

Dr Ibrahim on the Study of Eftilagimod Alpha Plus Paclitaxel in HER2-Negative or -Low Breast Cancer

Nuhad K. Ibrahim, MD, discusses the investigation of eftilagimod alpha plus in hormone receptor–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial.
....

United States , Nuhadk Ibrahim , Division Of Cancer Medicine , Department Of Breast Medical Oncology , University Of Texas Md Anderson Cancer Center , Breast Medical Oncology , Cancer Medicine , Cancer Center , Patients With Breast Cancer , Her2 Negative , Her2 Low , Breast Cancer , Eftilagimod Alpha , Ct05747794 , Phase 3 Aipac 003 Trial ,

Toxicity Profile With Trastuzumab Deruxtecan Proves Consistent, Manageable in HER2-Low Metastatic Breast Cancer

Treatment with trastuzumab deruxtecan resulted in lower exposure-adjusted incidence rates per patient-year of treatment-emergent adverse effects compared with treatment of physician’s choice in patients with HER2-low unresectable and/or metastatic breast cancer, according to safety analysis from the phase 3 DESTINY-Breast04 trial. ....

United States , San Francisco , Pionyr Immunotherapeutics , Daiichi Sankyo , Taiho Oncology Inc , Cancer Infusion Services , Breast Cancer Annual Congress , Novartis Pharmaceuticals Corporation , Daiichi Sankyo Inc , Sermonix Pharmaceuticals Inc , Helen Diller Family Comprehensive Cancer Center , Veru Inc , Roche Ag Genentech Inc , Department Of Medicine , Astellas Pharma Inc , Merck Co Inc , Gilead Sciences Inc , Cancer Annual Congress , Breast Oncology , Clinical Trials Education , Scorpion Therapeutics , Hoffmann La Roche , Gilead Sciences , Taiho Oncology , Esmo Breast Cancer Virtual Meeting , Breast Cancer ,